REAL TIME ULTRASONIC TISSUE IMAGING FOR PROSTATE CANCER

Spectrasonics成像公司提出合作的第一阶段工作 与河滨研究所(RRI)合作开发实时超声波 用于指示可疑的前列腺区域的系统 癌症。系统产生的实时图像将使更好地 引导针吸活组织检查。目前对活检的超声引导有 前列腺癌的敏感性和特异性都不能令人满意。作为一名 结果，绝大多数前列腺活检都是阴性的，并且可能 其中有一些错误地是负面的。RRI的研究表明，光谱- 作为提议系统基础的参数成像(SPI)方法可以改进 前列腺癌的检测率为50%，这可能会检测到额外的150,000 美国每年的癌症，减少重复活组织检查的需要，并允许 较早开始治疗。因为RRI的研究是在一个 研究环境，实现SPI对前列腺癌的明显潜力- 癌症检测需要1)在临床上验证SPI方法 使用实时成像系统设置，以及2)广泛的临床 传播。拟议的SBIR研究旨在通过以下方式采取这些步骤 开发一种使用颜色编码来描述的实时成像系统 可疑的前列腺区域。此颜色编码将基于 超声射频回波信号的频谱分析。我们期待着那次活检 通过提高敏感度和可控性可显著提高疗效 这种活检引导图像的特异性。这项建议的第一阶段工作 将寻求1)确定实时的最佳实施方法 组织类型成像，2)SPI技术与主机B超的接口 仪表，3)制定PI系统规范，4)计划第二阶段 原型建设的努力。 建议的商业应用： 仅在美国，每年就有超过100万例前列腺活检。 大约70%是阴性的，超过一半的阴性活检是 假的。重复活检与阳性活检的发生率几乎相同。 作为最初的活组织检查。不必要的重复活组织检查和漏诊的癌症 巨大的美元成本和耐心的风险。此时将显示建议的SPI方法 能够将癌症检测提高50%，这应该会使SPI非常 在商业上有吸引力，在医学上也有价值。

Spectrasonics Imaging, Inc. proposes a Phase I effort in collaboration with Riverside Research Institute (RRI) to develop a real-time ultrasonic system for indicating regions of the prostate that are suspicious for cancer. Real-time images produced by the system will enable better guidance of needle biopsies. Current ultrasonic guidance of biopsies has an unsatisfactory sensitivity and specificity for prostate cancer. As a consequence, the great majority of prostate biopsies are negative, and may of them are falsely negative. Studies by RRI suggest that the Spectral- Parameter Imaging (SPI) methods underlying the proposed system can improve detection of prostate cancer by 50%, which could detect 150,000 additional cancer annually in the US, reduce the need for repeat biopsies, and permit earlier initiation of treatment. Because RRI's studies are performed in a research setting, achieving the apparent potential of SPI for prostate- cancer detection requires 1) validation of the SPI methods in a clinical setting using a real-time imaging system, and 2) widespread clinical dissemination. The proposed SBIR study seeks to take these steps by developing a real-time imaging system that uses color encoding to depict suspicious regions of the prostate. This color-encoding will be based on spectrum analysis of ultrasonic rf echo signals. We anticipate that biopsy efficacy can be markedly improved through increases in the sensitivity and specificity of such biopsy-guidance images. This proposed Phase I effort will seek to 1) identify the optimal implementation approach for real-time tissue-type imaging, 2) interface the SPI technology with "host" B-mode instruments, 3) formulate PI system specifications, and 4) plan Phase II prototype-construction efforts. Proposed commercial applications: Over 1,000,000 prostate biopsies occur annually in the US alone. Approximately 70% are negative, and over half of the negative biopsies are false. Repeat biopsies have almost the same incidence of positive biopsies as initial biopsies. Unnecessary repeat biopsies and missed cancers impose an enormous dollar cost and patient risk. The proposed SPI methods appear capable of improving cancer detection by 50%, which should make SPI very attractive commercially and valuable medically.